
NASDAQHealthcareMedical - Devices
Latest quote
$1.29
−$0.03 · -2.27%
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
Latest quote
$1.29
−$0.03 · -2.27%
After-hours
$1.2885
−$0.0015 · -0.12%
Sep 9, 7:47 PM ET
Regular session · ET · Market data may be delayed.
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
Day range
Current $1.29
52-week range
Current $1.29
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
57
Fair Value
Sentiment
43
Mixed
Risk
77
High Risk
Momentum
48
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
Day range
Current $1.29
52-week range
Current $1.29
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 160.01M USD | 154.01M USD | 200.52M USD | 128.3M USD | 130.51M USD |
| Cost of goods sold | 109.33M USD | 116.73M USD | 147.74M USD | 79.27M USD | 71.65M USD |
| Gross profit | 50.67M USD | 37.28M USD | 52.78M USD | 49.04M USD | 58.86M USD |
| Research and development | 97.31M USD | 134.92M USD | 187.17M USD | 193M USD | 112.9M USD |
| Selling, general, and administrative | 141.49M USD | 175.02M USD | 169.82M USD | 160.85M USD | 124.12M USD |
| Operating expenses | 608.24M USD | 511.6M USD | 387.25M USD | 356.23M USD | 269.3M USD |
| Interest expense | 6.95M USD | 13.41M USD | 14.34M USD | 14.69M USD | 12.53M USD |
| Depreciation and amortization | 504.91M USD | 53.35M USD | 32.69M USD | 17.32M USD | 11.59M USD |
| Operating income | −557.56M USD | −474.31M USD | −334.47M USD | −307.2M USD | −210.44M USD |
| Net income | −546.38M USD | −309.85M USD | −306.74M USD | −314.25M USD | −181.22M USD |
Company facts updated Sep 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$1.18
8.53% downsideFunds reporting this stock among their holdings, ordered by reported position size.
ARK Innovation ETFARKK16.68M0.25%5.56B USD0.75%$84.56-1.77%
ARK Genomic Revolution ETFARKG14.57M0.74%1.56B USD0.75%$46.31-1.15%
Vanguard Morningstar Total Stock Market ETFVTI13.35M0.00%2.3T USD0.03%$375.56-0.54%
iShares Russell 2000 ETFIWM9.41M0.01%80.51B USD0.19%$290.64-1.37%
Vanguard Extended Market ETFVXF5.02M0.01%93.7B USD0.05%$238.67-1.11%
iShares Russell 2000 Growth ETFIWO3.2M0.02%14.7B USD0.24%$370.95-1.63%
iShares Biotechnology ETFIBB2.83M0.03%10.73B USD0.44%$205.49-0.89%
Vanguard Russell 2000 ETFVTWO2.21M0.01%17.4B USD0.06%$117.51-1.37%
ARK Innovation ETFARKK
ARK Genomic Revolution ETFARKG
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
iShares Biotechnology ETFIBB
Vanguard Russell 2000 ETFVTWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.